Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S007 - Advanced Systemic Therapeutics

Friday, July 27; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Determine and identify strategies for optimizing management of systemic therapies to reduce concerns and bias in treating patients of all ages with challenging dermatological conditions.
  • Recognize both conventional and potential applications of systemic therapies in the approach to dermatological conditions.
  • Select therapeutic options to modify a disease process in addition to alleviate symptoms based on the immune mechanisms that create them.

Description

“Don’t be afraid” should be the take home message for attendees of this session. Dermatologists need to make sure they are current in the correct and potential uses of the latest systemic therapies. Clinicians of all levels of training and practice setting need to optimize therapeutic regimens for patients with aggressive and challenging disorders as well as routine conditions, or risk losing these patients to other specialists that are “not afraid.” As the understanding of immune system pathways, cytokine balances, and cellular interactions continues to expand, so must the potential applications of systemic therapies. Our current therapeutic regimens are only as efficacious as our comfort with their utilities, which can only begin with matching the mechanisms of action as well as the safety profiles. Many newer agents have evolved from experimental and conceptual to readily available therapeutic modalities. The goals of this session are to review fundamentals of systemic therapeutics including appropriate dosage strategies, laboratory monitoring, and most importantly to explore various disease classifications within dermatology where systemic approaches are necessary. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment credits. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Bhatia, Neal D., MD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); Allergan, Inc – C(H); Almirall – C(H); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – I(Grants/Research Funding); Biofrontera AG – C(H); BioPharmX – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Crown Laboratories, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H); Glenmark Generics Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – C(H); ISDIN – C(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); LEO Pharma, US – I(Grants/Research Funding); Mayne Pharma Group – C(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Ortho Dermatologics – C(H); Par Pharmaceutical – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – C(H); Promius Pharma, LLC – A(H); Realm Therapeutics – I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Skinfix, Inc. – A(H); Sol-Gel Technologies – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Strata Skin Sciences – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Jackson, J. Mark, MD: AbbVie – C(H), I(Grants/Research Funding); Accuitis, Inc – C(Fees), C(SO); Amgen – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); Johnson & Johnson Pharmaceutical Research & Development – I(Grants/Research Funding); Lilly ICOS LLC – C(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Promius Pharmaceuticals – C(H); Ralexar Therapeutics, Inc – C(Fees), C(SO);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Murase, Jenny Eileen, MD: Dermira – C(H); Ferndale Laboratories, Inc. – C(H); Regeneron – SH(ST); UCB – C(H);
  • Patel, Anisha, MD: Spectrum – C(Fees);
  • Rosen, Theodore, MD: Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
  • Schlosser, Bethanee Jean, MD, PhD: Allergan, Inc – A(H), SP(H); Beiersdorf, Inc. – A(H); Decision Support in Medicine, LLC – O(H); UCB – A(H); UpToDate, Inc – O(H);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Schedule
Friday, July 27
1:00 PM
Dr. Bhatia / Introduction and Housekeeping
1:01 PM
Dr. Jackson / Systemic Therapeutics in Dermatology: Just Do It!
1:20 PM
Dr. Murase / Safe Medical Management of Skin Disease in Pregnancy
2:00 PM
Dr. Schlosser / Novel Uses of Hormonal Therapies
2:20 PM
Dr. Patel / Systemic Therapies for Medical Oncology
2:40 PM
Dr. Kircik / Who’s afraid of big bad biologics?
3:00 PM
Dr. Lebwohl / Do you know JAK?
3:20 PM
Dr. Tomecki / Advances in ID Rx: Real and Imagined
3:40 PM
Dr. Rosen / Innovations in Systemic Therapeutics
Event Details
  • Date
    Friday, July 27
  • Time
    1:00 PM - 4:00 PM
  • Location
    Grand Ballroom EF
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Neal D. Bhatia, MD, FAAD
Speakers
  • Anisha Patel, MD, FAAD - Handout
  • Bethanee Jean Schlosser, MD, PhD, FAAD - Handout
  • J. Mark Jackson, MD, FAAD - Handout
  • Jenny Eileen Murase, MD, FAAD - Handout
  • Kenneth J. Tomecki, MD, FAAD
  • Leon H. Kircik, MD, FAAD - Handout
  • Mark Lebwohl, MD, FAAD - Handout
  • Theodore Rosen, MD, FAAD - Handout